Stockreport

Esperion Completes Patient Enrollment in Global Pivotal Phase 3 Program for Bempedoic Acid

Esperion Therapeutics, Inc.  (ESPR) 
Last esperion therapeutics, inc. earnings: 2/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.esperion.com
PDF – Pivotal Phase 3 Top-Line Results for Bempedoic Acid Expected in the Second and Third Quarters of 2018 –– NDA Submission for LDL-C Lowering Indication for Bempedoic Aci [Read more]